Maylan was expected to benefit from the recall by its competitor Sanofi, according to a report published in the Fierce Pharma newsletter of 2 November 2015: "...it is very hard to see Auvi-Q returning to the market, as it will need to be redesigned and face uphill battle to recapture patient trust after the recall," Bernstein analyst Ronny Gal wrote in a note to clients.